nodes	percent_of_prediction	percent_of_DWPC	metapath
Dalfampridine—KCNQ4—ear—skin cancer	0.0342	0.068	CbGeAlD
Dalfampridine—KCNC1—nerve—skin cancer	0.0215	0.0428	CbGeAlD
Dalfampridine—KCNQ1—ear—skin cancer	0.0196	0.0391	CbGeAlD
Dalfampridine—KCNS3—hair follicle—skin cancer	0.0141	0.028	CbGeAlD
Dalfampridine—Pharyngolaryngeal pain—Imiquimod—skin cancer	0.0135	0.0271	CcSEcCtD
Dalfampridine—Laryngeal pain—Imiquimod—skin cancer	0.0133	0.0268	CcSEcCtD
Dalfampridine—KCNA1—nerve—skin cancer	0.0128	0.0255	CbGeAlD
Dalfampridine—KCNF1—nipple—skin cancer	0.0109	0.0217	CbGeAlD
Dalfampridine—KCNS2—female reproductive system—skin cancer	0.0101	0.0201	CbGeAlD
Dalfampridine—KCNB1—epithelium—skin cancer	0.00997	0.0198	CbGeAlD
Dalfampridine—KCNB2—head—skin cancer	0.00992	0.0197	CbGeAlD
Dalfampridine—KCNH4—head—skin cancer	0.00992	0.0197	CbGeAlD
Dalfampridine—KCNG4—head—skin cancer	0.00992	0.0197	CbGeAlD
Dalfampridine—KCNC3—epithelium—skin cancer	0.00968	0.0193	CbGeAlD
Dalfampridine—KCNS3—nipple—skin cancer	0.00954	0.019	CbGeAlD
Dalfampridine—Balance disorder—Fluorouracil—skin cancer	0.00918	0.0185	CcSEcCtD
Dalfampridine—KCNH5—head—skin cancer	0.00907	0.018	CbGeAlD
Dalfampridine—KCNS1—epithelium—skin cancer	0.00896	0.0178	CbGeAlD
Dalfampridine—KCNG3—lymphoid tissue—skin cancer	0.0089	0.0177	CbGeAlD
Dalfampridine—Connective tissue disorder—Vismodegib—skin cancer	0.00852	0.0171	CcSEcCtD
Dalfampridine—KCNA6—head—skin cancer	0.00843	0.0168	CbGeAlD
Dalfampridine—KCNS2—head—skin cancer	0.00843	0.0168	CbGeAlD
Dalfampridine—KCNV1—head—skin cancer	0.00793	0.0158	CbGeAlD
Dalfampridine—KCNV2—head—skin cancer	0.00751	0.0149	CbGeAlD
Dalfampridine—Back pain—Vismodegib—skin cancer	0.0073	0.0147	CcSEcCtD
Dalfampridine—KCNA3—lymphoid tissue—skin cancer	0.00725	0.0144	CbGeAlD
Dalfampridine—KCNC2—head—skin cancer	0.00717	0.0143	CbGeAlD
Dalfampridine—KCNG3—head—skin cancer	0.00717	0.0143	CbGeAlD
Dalfampridine—KCNH1—head—skin cancer	0.00717	0.0143	CbGeAlD
Dalfampridine—KCNC1—mammalian vulva—skin cancer	0.00714	0.0142	CbGeAlD
Dalfampridine—KCNQ1—neck—skin cancer	0.00695	0.0138	CbGeAlD
Dalfampridine—KCNA5—connective tissue—skin cancer	0.00691	0.0137	CbGeAlD
Dalfampridine—KCNS3—epithelium—skin cancer	0.00643	0.0128	CbGeAlD
Dalfampridine—KCNG1—head—skin cancer	0.00639	0.0127	CbGeAlD
Dalfampridine—KCNH3—head—skin cancer	0.00639	0.0127	CbGeAlD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00638	0.0128	CcSEcCtD
Dalfampridine—KCND1—female reproductive system—skin cancer	0.00636	0.0127	CbGeAlD
Dalfampridine—KCNB1—head—skin cancer	0.00619	0.0123	CbGeAlD
Dalfampridine—KCNH8—head—skin cancer	0.00619	0.0123	CbGeAlD
Dalfampridine—KCNS3—skin of body—skin cancer	0.00611	0.0122	CbGeAlD
Dalfampridine—Nervous system disorder—Vismodegib—skin cancer	0.00604	0.0121	CcSEcCtD
Dalfampridine—KCNC3—head—skin cancer	0.00601	0.0119	CbGeAlD
Dalfampridine—Skin disorder—Vismodegib—skin cancer	0.00598	0.012	CcSEcCtD
Dalfampridine—Infestation—Vemurafenib—skin cancer	0.00596	0.012	CcSEcCtD
Dalfampridine—Infestation NOS—Vemurafenib—skin cancer	0.00596	0.012	CcSEcCtD
Dalfampridine—KCNQ5—female reproductive system—skin cancer	0.00595	0.0118	CbGeAlD
Dalfampridine—KCNA4—head—skin cancer	0.00584	0.0116	CbGeAlD
Dalfampridine—KCNA3—head—skin cancer	0.00584	0.0116	CbGeAlD
Dalfampridine—KCNS3—mammalian vulva—skin cancer	0.00557	0.0111	CbGeAlD
Dalfampridine—KCNS1—head—skin cancer	0.00556	0.0111	CbGeAlD
Dalfampridine—KCNA2—head—skin cancer	0.00556	0.0111	CbGeAlD
Dalfampridine—Dyspepsia—Vismodegib—skin cancer	0.00542	0.0109	CcSEcCtD
Dalfampridine—Pharyngolaryngeal pain—Docetaxel—skin cancer	0.00537	0.0108	CcSEcCtD
Dalfampridine—KCNC4—head—skin cancer	0.00532	0.0106	CbGeAlD
Dalfampridine—KCND1—head—skin cancer	0.00532	0.0106	CbGeAlD
Dalfampridine—Laryngeal pain—Docetaxel—skin cancer	0.00532	0.0107	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00532	0.0107	CcSEcCtD
Dalfampridine—Constipation—Vismodegib—skin cancer	0.00526	0.0106	CcSEcCtD
Dalfampridine—Connective tissue disorder—Vemurafenib—skin cancer	0.00526	0.0106	CcSEcCtD
Dalfampridine—KCNH7—head—skin cancer	0.00511	0.0102	CbGeAlD
Dalfampridine—KCNQ4—head—skin cancer	0.00511	0.0102	CbGeAlD
Dalfampridine—KCNC1—head—skin cancer	0.00511	0.0102	CbGeAlD
Dalfampridine—Infestation—Imiquimod—skin cancer	0.00509	0.0102	CcSEcCtD
Dalfampridine—Infestation NOS—Imiquimod—skin cancer	0.00509	0.0102	CcSEcCtD
Dalfampridine—KCNQ5—head—skin cancer	0.00497	0.00988	CbGeAlD
Dalfampridine—Urinary tract infection—Imiquimod—skin cancer	0.00494	0.00994	CcSEcCtD
Dalfampridine—KCNA5—female reproductive system—skin cancer	0.00487	0.00969	CbGeAlD
Dalfampridine—Angiopathy—Vemurafenib—skin cancer	0.00486	0.00977	CcSEcCtD
Dalfampridine—Mediastinal disorder—Vemurafenib—skin cancer	0.00483	0.00971	CcSEcCtD
Dalfampridine—KCNQ3—female reproductive system—skin cancer	0.00477	0.00949	CbGeAlD
Dalfampridine—KCNF1—head—skin cancer	0.00455	0.00905	CbGeAlD
Dalfampridine—Back pain—Vemurafenib—skin cancer	0.00451	0.00907	CcSEcCtD
Dalfampridine—Connective tissue disorder—Imiquimod—skin cancer	0.00449	0.00902	CcSEcCtD
Dalfampridine—Asthenia—Vismodegib—skin cancer	0.00442	0.00889	CcSEcCtD
Dalfampridine—KCNQ2—female reproductive system—skin cancer	0.00439	0.00874	CbGeAlD
Dalfampridine—KCNH6—female reproductive system—skin cancer	0.00436	0.00866	CbGeAlD
Dalfampridine—Angiopathy—Imiquimod—skin cancer	0.00414	0.00833	CcSEcCtD
Dalfampridine—Immune system disorder—Imiquimod—skin cancer	0.00412	0.0083	CcSEcCtD
Dalfampridine—Mediastinal disorder—Imiquimod—skin cancer	0.00411	0.00828	CcSEcCtD
Dalfampridine—KCNQ1—mammalian vulva—skin cancer	0.0041	0.00816	CbGeAlD
Dalfampridine—Chest discomfort—Docetaxel—skin cancer	0.0041	0.00824	CcSEcCtD
Dalfampridine—KCNA3—lymph node—skin cancer	0.00409	0.00814	CbGeAlD
Dalfampridine—KCNA5—head—skin cancer	0.00407	0.0081	CbGeAlD
Dalfampridine—Mental disorder—Imiquimod—skin cancer	0.004	0.00805	CcSEcCtD
Dalfampridine—KCNS3—head—skin cancer	0.00399	0.00793	CbGeAlD
Dalfampridine—KCNQ3—head—skin cancer	0.00399	0.00793	CbGeAlD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00394	0.00793	CcSEcCtD
Dalfampridine—Vomiting—Vismodegib—skin cancer	0.00391	0.00787	CcSEcCtD
Dalfampridine—KCNA2—lymph node—skin cancer	0.00389	0.00774	CbGeAlD
Dalfampridine—Rash—Vismodegib—skin cancer	0.00388	0.00781	CcSEcCtD
Dalfampridine—Dermatitis—Vismodegib—skin cancer	0.00388	0.0078	CcSEcCtD
Dalfampridine—Back pain—Imiquimod—skin cancer	0.00384	0.00773	CcSEcCtD
Dalfampridine—Anaphylactic shock—Vemurafenib—skin cancer	0.0038	0.00765	CcSEcCtD
Dalfampridine—Infection—Vemurafenib—skin cancer	0.00378	0.0076	CcSEcCtD
Dalfampridine—Nervous system disorder—Vemurafenib—skin cancer	0.00373	0.0075	CcSEcCtD
Dalfampridine—KCNC4—lymph node—skin cancer	0.00372	0.0074	CbGeAlD
Dalfampridine—Skin disorder—Vemurafenib—skin cancer	0.00369	0.00743	CcSEcCtD
Dalfampridine—KCNQ2—head—skin cancer	0.00367	0.0073	CbGeAlD
Dalfampridine—Nausea—Vismodegib—skin cancer	0.00366	0.00736	CcSEcCtD
Dalfampridine—KCNH6—head—skin cancer	0.00364	0.00724	CbGeAlD
Dalfampridine—Angioedema—Imiquimod—skin cancer	0.00363	0.00731	CcSEcCtD
Dalfampridine—Hypotension—Vemurafenib—skin cancer	0.00355	0.00715	CcSEcCtD
Dalfampridine—KCNQ1—female reproductive system—skin cancer	0.00351	0.00698	CbGeAlD
Dalfampridine—KCNQ5—lymph node—skin cancer	0.00348	0.00692	CbGeAlD
Dalfampridine—KCND2—head—skin cancer	0.00348	0.00691	CbGeAlD
Dalfampridine—Convulsion—Imiquimod—skin cancer	0.00344	0.00693	CcSEcCtD
Dalfampridine—Chest pain—Imiquimod—skin cancer	0.00338	0.00681	CcSEcCtD
Dalfampridine—Anxiety—Imiquimod—skin cancer	0.00337	0.00678	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00336	0.00676	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00328	0.00661	CcSEcCtD
Dalfampridine—Nasopharyngitis—Fluorouracil—skin cancer	0.00326	0.00655	CcSEcCtD
Dalfampridine—Constipation—Vemurafenib—skin cancer	0.00325	0.00654	CcSEcCtD
Dalfampridine—Infection—Imiquimod—skin cancer	0.00322	0.00648	CcSEcCtD
Dalfampridine—Nervous system disorder—Imiquimod—skin cancer	0.00318	0.0064	CcSEcCtD
Dalfampridine—Skin disorder—Imiquimod—skin cancer	0.00315	0.00634	CcSEcCtD
Dalfampridine—Infestation NOS—Temozolomide—skin cancer	0.00305	0.00613	CcSEcCtD
Dalfampridine—Infestation—Temozolomide—skin cancer	0.00305	0.00613	CcSEcCtD
Dalfampridine—KCNA1—head—skin cancer	0.00305	0.00606	CbGeAlD
Dalfampridine—KCND3—head—skin cancer	0.00303	0.00603	CbGeAlD
Dalfampridine—Urinary tract infection—Temozolomide—skin cancer	0.00296	0.00596	CcSEcCtD
Dalfampridine—KCNQ1—head—skin cancer	0.00293	0.00583	CbGeAlD
Dalfampridine—Insomnia—Imiquimod—skin cancer	0.00293	0.0059	CcSEcCtD
Dalfampridine—Paraesthesia—Imiquimod—skin cancer	0.00291	0.00586	CcSEcCtD
Dalfampridine—Dyspnoea—Imiquimod—skin cancer	0.00289	0.00582	CcSEcCtD
Dalfampridine—Dyspepsia—Imiquimod—skin cancer	0.00286	0.00574	CcSEcCtD
Dalfampridine—KCNA5—lymph node—skin cancer	0.00285	0.00567	CbGeAlD
Dalfampridine—Infestation NOS—Fluorouracil—skin cancer	0.00281	0.00565	CcSEcCtD
Dalfampridine—Infestation—Fluorouracil—skin cancer	0.00281	0.00565	CcSEcCtD
Dalfampridine—Hypersensitivity—Vemurafenib—skin cancer	0.0028	0.00564	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Imiquimod—skin cancer	0.0028	0.00563	CcSEcCtD
Dalfampridine—KCNS3—lymph node—skin cancer	0.00279	0.00555	CbGeAlD
Dalfampridine—Urinary tract infection—Fluorouracil—skin cancer	0.00273	0.00549	CcSEcCtD
Dalfampridine—Asthenia—Vemurafenib—skin cancer	0.00273	0.00549	CcSEcCtD
Dalfampridine—Connective tissue disorder—Temozolomide—skin cancer	0.00269	0.00541	CcSEcCtD
Dalfampridine—KCNH2—nipple—skin cancer	0.00268	0.00532	CbGeAlD
Dalfampridine—Feeling abnormal—Imiquimod—skin cancer	0.00267	0.00538	CcSEcCtD
Dalfampridine—Urticaria—Imiquimod—skin cancer	0.00258	0.00518	CcSEcCtD
Dalfampridine—Dizziness—Vemurafenib—skin cancer	0.00252	0.00506	CcSEcCtD
Dalfampridine—Angiopathy—Temozolomide—skin cancer	0.00248	0.00499	CcSEcCtD
Dalfampridine—Immune system disorder—Temozolomide—skin cancer	0.00247	0.00497	CcSEcCtD
Dalfampridine—Mediastinal disorder—Temozolomide—skin cancer	0.00247	0.00496	CcSEcCtD
Dalfampridine—Vomiting—Vemurafenib—skin cancer	0.00242	0.00486	CcSEcCtD
Dalfampridine—Chest pain—Bleomycin—skin cancer	0.0024	0.00484	CcSEcCtD
Dalfampridine—Rash—Vemurafenib—skin cancer	0.0024	0.00482	CcSEcCtD
Dalfampridine—Mental disorder—Temozolomide—skin cancer	0.0024	0.00482	CcSEcCtD
Dalfampridine—Dermatitis—Vemurafenib—skin cancer	0.0024	0.00482	CcSEcCtD
Dalfampridine—Hypersensitivity—Imiquimod—skin cancer	0.00239	0.00481	CcSEcCtD
Dalfampridine—Headache—Vemurafenib—skin cancer	0.00238	0.00479	CcSEcCtD
Dalfampridine—Nasopharyngitis—Docetaxel—skin cancer	0.00235	0.00473	CcSEcCtD
Dalfampridine—Asthenia—Imiquimod—skin cancer	0.00233	0.00468	CcSEcCtD
Dalfampridine—Confusional state—Bleomycin—skin cancer	0.00232	0.00467	CcSEcCtD
Dalfampridine—Anaphylactic shock—Bleomycin—skin cancer	0.0023	0.00464	CcSEcCtD
Dalfampridine—Back pain—Temozolomide—skin cancer	0.0023	0.00463	CcSEcCtD
Dalfampridine—Infection—Bleomycin—skin cancer	0.00229	0.00461	CcSEcCtD
Dalfampridine—Nausea—Vemurafenib—skin cancer	0.00226	0.00454	CcSEcCtD
Dalfampridine—Tremor—Temozolomide—skin cancer	0.00223	0.00449	CcSEcCtD
Dalfampridine—Angioedema—Temozolomide—skin cancer	0.00218	0.00438	CcSEcCtD
Dalfampridine—Hypotension—Bleomycin—skin cancer	0.00215	0.00433	CcSEcCtD
Dalfampridine—Dizziness—Imiquimod—skin cancer	0.00215	0.00431	CcSEcCtD
Dalfampridine—Infection—Dactinomycin—skin cancer	0.00214	0.00429	CcSEcCtD
Dalfampridine—KCND3—lymph node—skin cancer	0.00212	0.00422	CbGeAlD
Dalfampridine—Paraesthesia—Bleomycin—skin cancer	0.00207	0.00416	CcSEcCtD
Dalfampridine—Convulsion—Temozolomide—skin cancer	0.00206	0.00415	CcSEcCtD
Dalfampridine—Vomiting—Imiquimod—skin cancer	0.00206	0.00415	CcSEcCtD
Dalfampridine—Dyspnoea—Bleomycin—skin cancer	0.00205	0.00413	CcSEcCtD
Dalfampridine—KCNQ1—lymph node—skin cancer	0.00205	0.00409	CbGeAlD
Dalfampridine—Rash—Imiquimod—skin cancer	0.00205	0.00411	CcSEcCtD
Dalfampridine—Dermatitis—Imiquimod—skin cancer	0.00204	0.00411	CcSEcCtD
Dalfampridine—Headache—Imiquimod—skin cancer	0.00203	0.00409	CcSEcCtD
Dalfampridine—Infestation NOS—Docetaxel—skin cancer	0.00203	0.00408	CcSEcCtD
Dalfampridine—Infestation—Docetaxel—skin cancer	0.00203	0.00408	CcSEcCtD
Dalfampridine—Anxiety—Temozolomide—skin cancer	0.00202	0.00406	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00201	0.00405	CcSEcCtD
Dalfampridine—Confusional state—Temozolomide—skin cancer	0.00196	0.00394	CcSEcCtD
Dalfampridine—Anaphylactic shock—Temozolomide—skin cancer	0.00194	0.00391	CcSEcCtD
Dalfampridine—Infection—Temozolomide—skin cancer	0.00193	0.00388	CcSEcCtD
Dalfampridine—Nausea—Imiquimod—skin cancer	0.00193	0.00388	CcSEcCtD
Dalfampridine—Nervous system disorder—Temozolomide—skin cancer	0.00191	0.00383	CcSEcCtD
Dalfampridine—Convulsion—Fluorouracil—skin cancer	0.0019	0.00382	CcSEcCtD
Dalfampridine—Feeling abnormal—Bleomycin—skin cancer	0.0019	0.00382	CcSEcCtD
Dalfampridine—Skin disorder—Temozolomide—skin cancer	0.00189	0.0038	CcSEcCtD
Dalfampridine—Chest pain—Fluorouracil—skin cancer	0.00187	0.00376	CcSEcCtD
Dalfampridine—Urticaria—Bleomycin—skin cancer	0.00183	0.00368	CcSEcCtD
Dalfampridine—Confusional state—Fluorouracil—skin cancer	0.00181	0.00363	CcSEcCtD
Dalfampridine—Anaphylactic shock—Fluorouracil—skin cancer	0.00179	0.0036	CcSEcCtD
Dalfampridine—Connective tissue disorder—Docetaxel—skin cancer	0.00179	0.0036	CcSEcCtD
Dalfampridine—Infection—Fluorouracil—skin cancer	0.00178	0.00358	CcSEcCtD
Dalfampridine—Feeling abnormal—Dactinomycin—skin cancer	0.00177	0.00356	CcSEcCtD
Dalfampridine—Insomnia—Temozolomide—skin cancer	0.00176	0.00354	CcSEcCtD
Dalfampridine—Nervous system disorder—Fluorouracil—skin cancer	0.00176	0.00353	CcSEcCtD
Dalfampridine—Paraesthesia—Temozolomide—skin cancer	0.00175	0.00351	CcSEcCtD
Dalfampridine—Dyspnoea—Temozolomide—skin cancer	0.00173	0.00349	CcSEcCtD
Dalfampridine—Dyspepsia—Temozolomide—skin cancer	0.00171	0.00344	CcSEcCtD
Dalfampridine—Hypersensitivity—Bleomycin—skin cancer	0.0017	0.00342	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00168	0.00338	CcSEcCtD
Dalfampridine—Hypotension—Fluorouracil—skin cancer	0.00167	0.00337	CcSEcCtD
Dalfampridine—Constipation—Temozolomide—skin cancer	0.00166	0.00334	CcSEcCtD
Dalfampridine—Asthenia—Bleomycin—skin cancer	0.00165	0.00333	CcSEcCtD
Dalfampridine—Angiopathy—Docetaxel—skin cancer	0.00165	0.00332	CcSEcCtD
Dalfampridine—Immune system disorder—Docetaxel—skin cancer	0.00164	0.00331	CcSEcCtD
Dalfampridine—Mediastinal disorder—Docetaxel—skin cancer	0.00164	0.0033	CcSEcCtD
Dalfampridine—Insomnia—Fluorouracil—skin cancer	0.00162	0.00326	CcSEcCtD
Dalfampridine—Paraesthesia—Fluorouracil—skin cancer	0.00161	0.00323	CcSEcCtD
Dalfampridine—Feeling abnormal—Temozolomide—skin cancer	0.0016	0.00322	CcSEcCtD
Dalfampridine—Dyspnoea—Fluorouracil—skin cancer	0.0016	0.00321	CcSEcCtD
Dalfampridine—Mental disorder—Docetaxel—skin cancer	0.00159	0.00321	CcSEcCtD
Dalfampridine—Hypersensitivity—Dactinomycin—skin cancer	0.00158	0.00319	CcSEcCtD
Dalfampridine—Dyspepsia—Fluorouracil—skin cancer	0.00158	0.00317	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00155	0.00311	CcSEcCtD
Dalfampridine—Urticaria—Temozolomide—skin cancer	0.00154	0.00311	CcSEcCtD
Dalfampridine—Asthenia—Dactinomycin—skin cancer	0.00154	0.0031	CcSEcCtD
Dalfampridine—Back pain—Docetaxel—skin cancer	0.00153	0.00308	CcSEcCtD
Dalfampridine—Feeling abnormal—Fluorouracil—skin cancer	0.00148	0.00297	CcSEcCtD
Dalfampridine—Vomiting—Bleomycin—skin cancer	0.00147	0.00295	CcSEcCtD
Dalfampridine—Rash—Bleomycin—skin cancer	0.00145	0.00292	CcSEcCtD
Dalfampridine—Dermatitis—Bleomycin—skin cancer	0.00145	0.00292	CcSEcCtD
Dalfampridine—Hypersensitivity—Temozolomide—skin cancer	0.00143	0.00288	CcSEcCtD
Dalfampridine—Urticaria—Fluorouracil—skin cancer	0.00142	0.00286	CcSEcCtD
Dalfampridine—Asthenia—Temozolomide—skin cancer	0.00139	0.00281	CcSEcCtD
Dalfampridine—Convulsion—Docetaxel—skin cancer	0.00137	0.00276	CcSEcCtD
Dalfampridine—Nausea—Bleomycin—skin cancer	0.00137	0.00275	CcSEcCtD
Dalfampridine—Vomiting—Dactinomycin—skin cancer	0.00137	0.00275	CcSEcCtD
Dalfampridine—Rash—Dactinomycin—skin cancer	0.00136	0.00273	CcSEcCtD
Dalfampridine—Chest pain—Docetaxel—skin cancer	0.00135	0.00271	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00134	0.00269	CcSEcCtD
Dalfampridine—KCNH2—female reproductive system—skin cancer	0.00134	0.00266	CbGeAlD
Dalfampridine—Hypersensitivity—Fluorouracil—skin cancer	0.00132	0.00265	CcSEcCtD
Dalfampridine—Confusional state—Docetaxel—skin cancer	0.0013	0.00262	CcSEcCtD
Dalfampridine—Anaphylactic shock—Docetaxel—skin cancer	0.00129	0.0026	CcSEcCtD
Dalfampridine—Dizziness—Temozolomide—skin cancer	0.00129	0.00259	CcSEcCtD
Dalfampridine—Infection—Docetaxel—skin cancer	0.00128	0.00258	CcSEcCtD
Dalfampridine—Nausea—Dactinomycin—skin cancer	0.00128	0.00257	CcSEcCtD
Dalfampridine—Nervous system disorder—Docetaxel—skin cancer	0.00127	0.00255	CcSEcCtD
Dalfampridine—Skin disorder—Docetaxel—skin cancer	0.00126	0.00253	CcSEcCtD
Dalfampridine—Vomiting—Temozolomide—skin cancer	0.00124	0.00249	CcSEcCtD
Dalfampridine—Rash—Temozolomide—skin cancer	0.00123	0.00247	CcSEcCtD
Dalfampridine—Dermatitis—Temozolomide—skin cancer	0.00122	0.00246	CcSEcCtD
Dalfampridine—Headache—Temozolomide—skin cancer	0.00122	0.00245	CcSEcCtD
Dalfampridine—Hypotension—Docetaxel—skin cancer	0.00121	0.00243	CcSEcCtD
Dalfampridine—Dizziness—Fluorouracil—skin cancer	0.00118	0.00238	CcSEcCtD
Dalfampridine—Insomnia—Docetaxel—skin cancer	0.00117	0.00235	CcSEcCtD
Dalfampridine—Paraesthesia—Docetaxel—skin cancer	0.00116	0.00233	CcSEcCtD
Dalfampridine—Nausea—Temozolomide—skin cancer	0.00115	0.00232	CcSEcCtD
Dalfampridine—Dyspnoea—Docetaxel—skin cancer	0.00115	0.00232	CcSEcCtD
Dalfampridine—Vomiting—Fluorouracil—skin cancer	0.00114	0.00229	CcSEcCtD
Dalfampridine—Dyspepsia—Docetaxel—skin cancer	0.00114	0.00229	CcSEcCtD
Dalfampridine—Rash—Fluorouracil—skin cancer	0.00113	0.00227	CcSEcCtD
Dalfampridine—Dermatitis—Fluorouracil—skin cancer	0.00113	0.00227	CcSEcCtD
Dalfampridine—Headache—Fluorouracil—skin cancer	0.00112	0.00226	CcSEcCtD
Dalfampridine—KCNH2—head—skin cancer	0.00112	0.00222	CbGeAlD
Dalfampridine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00112	0.00224	CcSEcCtD
Dalfampridine—Constipation—Docetaxel—skin cancer	0.00111	0.00222	CcSEcCtD
Dalfampridine—CYP2E1—lymphoid tissue—skin cancer	0.00107	0.00213	CbGeAlD
Dalfampridine—Feeling abnormal—Docetaxel—skin cancer	0.00107	0.00214	CcSEcCtD
Dalfampridine—Nausea—Fluorouracil—skin cancer	0.00106	0.00214	CcSEcCtD
Dalfampridine—CYP2E1—female reproductive system—skin cancer	0.00103	0.00205	CbGeAlD
Dalfampridine—Hypersensitivity—Docetaxel—skin cancer	0.000952	0.00192	CcSEcCtD
Dalfampridine—Asthenia—Docetaxel—skin cancer	0.000927	0.00187	CcSEcCtD
Dalfampridine—CYP2E1—head—skin cancer	0.000861	0.00171	CbGeAlD
Dalfampridine—Dizziness—Docetaxel—skin cancer	0.000855	0.00172	CcSEcCtD
Dalfampridine—Vomiting—Docetaxel—skin cancer	0.000822	0.00165	CcSEcCtD
Dalfampridine—Rash—Docetaxel—skin cancer	0.000815	0.00164	CcSEcCtD
Dalfampridine—Dermatitis—Docetaxel—skin cancer	0.000814	0.00164	CcSEcCtD
Dalfampridine—Headache—Docetaxel—skin cancer	0.00081	0.00163	CcSEcCtD
Dalfampridine—KCNH2—lymph node—skin cancer	0.000783	0.00156	CbGeAlD
Dalfampridine—Nausea—Docetaxel—skin cancer	0.000768	0.00154	CcSEcCtD
